Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, September 22, 2015
Xcelience and Powdersize announced today the addition of the Netzsch Delta Vita media mills, a nanoparticle milling solution, to their arsenal of capabilities. For the first time, one CDMO
can provide solutions for a full range of particle size ...
read more
Monday, February 08, 2021
X-Chem has entered into a research collaboration and license agreement with Genentech.
read more
Thursday, January 04, 2024
X-Chem, a provider of innovative solutions in early-stage drug discovery, announced executive management team changes aimed at expanding its position as a premium provider of integrated services to drug hunters.
read more
Wednesday, February 15, 2017
X-Chem, Inc. has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease.
read more
Wednesday, January 17, 2018
X-Chem announced an expansion of their existing global drug discovery collaboration with AstraZeneca.
read more
Wednesday, January 06, 2016
X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, announced a multi-target collaboration with Sanofi.
read more
Thursday, August 10, 2023
X-Chem announced the addition of Karen Lackey as chief scientific officer (CSO) and David Hagerman as chief financial officer (CFO) to its global executive management team.
read more
X-Chem, a provider of DNA-encoded library (DEL)-based discovery services, has announced the global launch of its OpenDEX solution.
read more
Wednesday, March 30, 2016
X-Chem, a privately held biotechnology company applying its DNA-Encoded X-Chem (DEX™) drug discovery platform to generate novel therapeutics, has announced that a licensing option with Janssen Biotech, Inc., one of the Janssen Pharmaceutical ...
read more
X-Chem announced the establishment of a research partnership with Sironax, in which X-Chem will leverage its powerful DEL platform to support Sironax’s drug discovery pipeline.
read more
Tuesday, January 31, 2023
X-Chem, a provider of solutions for early-stage drug discovery, announced the expansion of its collaboration with Kymera Therapeutics, Inc. With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based ...
read more
Wednesday, April 03, 2024
X-Chem, a provider of solutions for early-stage drug discovery, announced the addition of Dr. Erin Davis as chief technology officer.
read more
Monday, February 01, 2021
X-Chem has acquired IntelliSyn, a Montreal-based drug discovery services company and its US-based sister company, AviSyn.
read more
Tuesday, December 05, 2023
X-Chem, a company specializing in drug discovery services, has proudly announced a significant milestone in drug discovery, marking the successful advancement of a development candidate by one of its partners.
read more
STA Pharmaceutical, a WuXi AppTec group company, has merged with WuXi AppTec’s Pharmaceutical Development Services division.
read more